BofA Securities Downgrades CureVac (CVAC) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts CVAC Hot Sheet
Price: $4.66 --0%
Rating Summary:
1 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
1 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
BofA Securities analyst Geoff Meacham downgraded CureVac (NASDAQ: CVAC) from Neutral to Underperform with a price target of $20.00.
For an analyst ratings summary and ratings history on CureVac click here. For more ratings news on CureVac click here.
Shares of CureVac closed at $21.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Central Bancompany (CBC) to Neutral
- Citi Downgrades Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) to Neutral
- Argus Downgrades Xylem (XYL) to Hold
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
